ASC-话题@MedSci

#ASC#

1352篇内容 | 3946人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1939152, encodeId=097d1939152a5, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, objectTitle=Prostate Cancer P D：CASC11能够促进前列腺癌细胞的侵袭性, objectType=article, longId=209621, objectId=151320962168, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=151320962168, replyNumber=0, likeNumber=58, createdTime=2022-01-04, rootId=0, userName=quxin068, userId=74808, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=151320962168, moduleTitle=Prostate Cancer P D：CASC11能够促进前列腺癌细胞的侵袭性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=151320962168)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1939163, encodeId=be56193916379, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, objectTitle=ASCO 2021：摘要概览与展望 1, objectType=article, longId=211709, objectId=59a1211e095b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=59a1211e095b, replyNumber=0, likeNumber=85, createdTime=2021-09-12, rootId=0, userName=quxin068, userId=74808, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=59a1211e095b, moduleTitle=ASCO 2021：摘要概览与展望 1, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=59a1211e095b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1939130, encodeId=6a10193913094, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, objectTitle=ASCO GI 2021：帕博利珠单抗+放化疗全程新辅助治疗局部晚期直肠癌，未能改善NAR评分（NRG-GI002研究）, objectType=article, longId=205931, objectId=2ebe20593162, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2ebe20593162, replyNumber=0, likeNumber=60, createdTime=2021-05-23, rootId=0, userName=quxin068, userId=74808, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2ebe20593162, moduleTitle=ASCO GI 2021：帕博利珠单抗+放化疗全程新辅助治疗局部晚期直肠癌，未能改善NAR评分（NRG-GI002研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2ebe20593162)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1939140, encodeId=62091939140da, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, objectTitle=ASCO GU 2021: Nivolumab联合Cabozantinib与舒尼替尼在晚期肾细胞癌中效果对比（CheckMate 9ER研究）, objectType=article, longId=207196, objectId=04c620e196a7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=04c620e196a7, replyNumber=0, likeNumber=74, createdTime=2021-12-02, rootId=0, userName=quxin068, userId=74808, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=04c620e196a7, moduleTitle=ASCO GU 2021: Nivolumab联合Cabozantinib与舒尼替尼在晚期肾细胞癌中效果对比（CheckMate 9ER研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=04c620e196a7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1939142, encodeId=e3691939142d3, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, objectTitle=ASCO GU 2021: 免疫联合靶向在晚期肾癌中大获成功，完成2年治疗的人群结果公布（KEYNOTE-426研究）, objectType=article, longId=207203, objectId=134820e203ba, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=134820e203ba, replyNumber=0, likeNumber=71, createdTime=2021-09-24, rootId=0, userName=quxin068, userId=74808, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=134820e203ba, moduleTitle=ASCO GU 2021: 免疫联合靶向在晚期肾癌中大获成功，完成2年治疗的人群结果公布（KEYNOTE-426研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=134820e203ba)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1939059, encodeId=8ad81939059b4, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, objectTitle=ASCO 2020：将老年医学评估和管理整合到癌症护理中可改善生活质量，减少老年患者的住院率, objectType=article, longId=194647, objectId=8edd19464e54, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8edd19464e54, replyNumber=0, likeNumber=59, createdTime=2021-03-27, rootId=0, userName=quxin068, userId=74808, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8edd19464e54, moduleTitle=ASCO 2020：将老年医学评估和管理整合到癌症护理中可改善生活质量，减少老年患者的住院率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8edd19464e54)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1939051, encodeId=f4db1939051c1, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, objectTitle=ASCO 2020：信达生物的抗PD-L1单抗TYVYT（Sintilimab）显着改善了食管鳞状细胞癌患者的总体生存率(ORIENT-2研究), objectType=article, longId=194241, objectId=a91619424150, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a91619424150, replyNumber=0, likeNumber=70, createdTime=2020-07-25, rootId=0, userName=quxin068, userId=74808, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a91619424150, moduleTitle=ASCO 2020：信达生物的抗PD-L1单抗TYVYT（Sintilimab）显着改善了食管鳞状细胞癌患者的总体生存率(ORIENT-2研究), moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a91619424150)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1939061, encodeId=6505193906150, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, objectTitle=Circ：Cardiovasc Inte：先天性心脏病心脏导管手术辐射暴露的纵向改善, objectType=article, longId=194685, objectId=d92d19468536, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d92d19468536, replyNumber=0, likeNumber=0, createdTime=2021-01-01, rootId=0, userName=quxin068, userId=74808, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d92d19468536, moduleTitle=Circ：Cardiovasc Inte：先天性心脏病心脏导管手术辐射暴露的纵向改善, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d92d19468536)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1939138, encodeId=5f99193913811, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, objectTitle=ASCO GU 2021: IL-15RαFc超激动剂N-803在对BCG反应的NMIBC膀胱癌原位癌患者中的研究（QUILT 3.032试验）, objectType=article, longId=207193, objectId=f13120e19316, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f13120e19316, replyNumber=0, likeNumber=82, createdTime=2021-08-08, rootId=0, userName=quxin068, userId=74808, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f13120e19316, moduleTitle=ASCO GU 2021: IL-15RαFc超激动剂N-803在对BCG反应的NMIBC膀胱癌原位癌患者中的研究（QUILT 3.032试验）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f13120e19316)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1939107, encodeId=063c193910e0c, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, objectTitle=J Vasc Surg ：间歇性跛行患者的饮食与踝肱指数、炎症和行走能力有关, objectType=article, longId=200964, objectId=dbd520096425, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dbd520096425, replyNumber=0, likeNumber=83, createdTime=2021-02-27, rootId=0, userName=quxin068, userId=74808, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dbd520096425, moduleTitle=J Vasc Surg ：间歇性跛行患者的饮食与踝肱指数、炎症和行走能力有关, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dbd520096425)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1939110, encodeId=69ae193911046, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, objectTitle=Catheter Cardiovasc Interv：微血管阻力指数评估罗伐他汀对胸痛且无阻塞性冠状动脉疾病的女性微血管功能的影响, objectType=article, longId=201319, objectId=0a6920131931, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0a6920131931, replyNumber=0, likeNumber=68, createdTime=2021-01-06, rootId=0, userName=quxin068, userId=74808, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0a6920131931, moduleTitle=Catheter Cardiovasc Interv：微血管阻力指数评估罗伐他汀对胸痛且无阻塞性冠状动脉疾病的女性微血管功能的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0a6920131931)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1939067, encodeId=a362193906ee0, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, objectTitle=ASCO 2020：HR+/HER2-晚期乳腺癌内脏转移时治疗的选择？, objectType=article, longId=195022, objectId=3d631950226f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3d631950226f, replyNumber=0, likeNumber=65, createdTime=2020-06-10, rootId=0, userName=quxin068, userId=74808, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3d631950226f, moduleTitle=ASCO 2020：HR+/HER2-晚期乳腺癌内脏转移时治疗的选择？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3d631950226f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1939090, encodeId=db4a1939090a9, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, objectTitle=ASCO 2020丨陈洁教授：纵使微小，也需努力前行，ASCO上NETs相关研究, objectType=article, longId=196206, objectId=552119620647, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=552119620647, replyNumber=0, likeNumber=73, createdTime=2021-01-04, rootId=0, userName=quxin068, userId=74808, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=552119620647, moduleTitle=ASCO 2020丨陈洁教授：纵使微小，也需努力前行，ASCO上NETs相关研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=552119620647)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1939122, encodeId=c524193912258, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, objectTitle=J Vasc Surg ：无症状颈动脉狭窄与脑灌注不足有关, objectType=article, longId=203986, objectId=482a20398685, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=482a20398685, replyNumber=0, likeNumber=67, createdTime=2021-03-19, rootId=0, userName=quxin068, userId=74808, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=482a20398685, moduleTitle=J Vasc Surg ：无症状颈动脉狭窄与脑灌注不足有关, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=482a20398685)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1939098, encodeId=df4a19390980a, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, objectTitle=2020 POST-ASCO：胶质母细胞瘤治疗的现状与未来, objectType=article, longId=198155, objectId=30771981557e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=30771981557e, replyNumber=0, likeNumber=63, createdTime=2020-11-06, rootId=0, userName=quxin068, userId=74808, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=30771981557e, moduleTitle=2020 POST-ASCO：胶质母细胞瘤治疗的现状与未来, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=30771981557e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1939111, encodeId=f32c193911137, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, objectTitle=FXR激动剂ASC42治疗NASH：美国FDA已批准IND, objectType=article, longId=202037, objectId=84d120203ed5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=84d120203ed5, replyNumber=0, likeNumber=68, createdTime=2020-10-31, rootId=0, userName=quxin068, userId=74808, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=84d120203ed5, moduleTitle=FXR激动剂ASC42治疗NASH：美国FDA已批准IND, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=84d120203ed5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1939065, encodeId=5d991939065eb, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, objectTitle=ASCO前沿 | 阿帕替尼在肝癌等实体瘤治疗中获得突破性进展, objectType=article, longId=194963, objectId=a117194963e1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a117194963e1, replyNumber=0, likeNumber=24, createdTime=2021-03-03, rootId=0, userName=quxin068, userId=74808, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a117194963e1, moduleTitle=ASCO前沿 | 阿帕替尼在肝癌等实体瘤治疗中获得突破性进展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a117194963e1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1939076, encodeId=438419390e697, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, objectTitle=OCC 2020丨颠覆性试验结果！鱼油用于ASCVD防治是时候了吗？, objectType=article, longId=195120, objectId=7e7b1951202f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7e7b1951202f, replyNumber=0, likeNumber=33, createdTime=2020-06-24, rootId=0, userName=quxin068, userId=74808, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7e7b1951202f, moduleTitle=OCC 2020丨颠覆性试验结果！鱼油用于ASCVD防治是时候了吗？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7e7b1951202f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1939068, encodeId=888219390687e, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, objectTitle=ASCO 2020：三阴性乳腺癌节拍化疗探索（SYSUCC-001研究）, objectType=article, longId=195026, objectId=3746195026a6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3746195026a6, replyNumber=0, likeNumber=106, createdTime=2020-12-02, rootId=0, userName=quxin068, userId=74808, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3746195026a6, moduleTitle=ASCO 2020：三阴性乳腺癌节拍化疗探索（SYSUCC-001研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3746195026a6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1939125, encodeId=9b6e193912571, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, objectTitle=赵冬：ASCVD一级预防，LDL-C目标值和安全性再探讨, objectType=article, longId=205507, objectId=1abc20550ed2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1abc20550ed2, replyNumber=0, likeNumber=127, createdTime=2021-07-23, rootId=0, userName=quxin068, userId=74808, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1abc20550ed2, moduleTitle=赵冬：ASCVD一级预防，LDL-C目标值和安全性再探讨, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1abc20550ed2)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

ASC

2020-05-29

quxin068 (审核中...)

前往app查看评论内容

#ASC#

Prostate Cancer P D：CASC11能够促进前列腺癌细胞的侵袭性

2022-01-04

quxin068 (审核中...)

前往app查看评论内容

#ASC#

ASCO 2021：摘要概览与展望 1

2021-09-12

quxin068 (审核中...)

前往app查看评论内容

#ASC#

ASCO GI 2021：帕博利珠单抗+放化疗全程新辅助治疗局部晚期直肠癌，未能改善NAR评分（NRG-GI002研究）

2021-05-23

quxin068 (审核中...)

前往app查看评论内容

#ASC#

ASCO GU 2021: Nivolumab联合Cabozantinib与舒尼替尼在晚期肾细胞癌中效果对比（CheckMate 9ER研究）

2021-12-02

quxin068 (审核中...)

前往app查看评论内容

#ASC#

ASCO GU 2021: 免疫联合靶向在晚期肾癌中大获成功，完成2年治疗的人群结果公布（KEYNOTE-426研究）

2021-09-24

quxin068 (审核中...)

前往app查看评论内容

#ASC#

ASCO 2020：将老年医学评估和管理整合到癌症护理中可改善生活质量，减少老年患者的住院率

2021-03-27

quxin068 (审核中...)

前往app查看评论内容

#ASC#

ASCO 2020：信达生物的抗PD-L1单抗TYVYT（Sintilimab）显着改善了食管鳞状细胞癌患者的总体生存率(ORIENT-2研究)

2020-07-25

quxin068 (审核中...)

前往app查看评论内容

#ASC#

Circ：Cardiovasc Inte：先天性心脏病心脏导管手术辐射暴露的纵向改善

2021-01-01

quxin068 (审核中...)

前往app查看评论内容

#ASC#

ASCO GU 2021: IL-15RαFc超激动剂N-803在对BCG反应的NMIBC膀胱癌原位癌患者中的研究（QUILT 3.032试验）

2021-08-08

quxin068 (审核中...)

前往app查看评论内容

#ASC#

J Vasc Surg ：间歇性跛行患者的饮食与踝肱指数、炎症和行走能力有关

2021-02-27

quxin068 (审核中...)

前往app查看评论内容

#ASC#

Catheter Cardiovasc Interv：微血管阻力指数评估罗伐他汀对胸痛且无阻塞性冠状动脉疾病的女性微血管功能的影响

2021-01-06

quxin068 (审核中...)

前往app查看评论内容

#ASC#

ASCO 2020：HR+/HER2-晚期乳腺癌内脏转移时治疗的选择？

2020-06-10

quxin068 (审核中...)

前往app查看评论内容

#ASC#

ASCO 2020丨陈洁教授：纵使微小，也需努力前行，ASCO上NETs相关研究

2021-01-04

quxin068 (审核中...)

前往app查看评论内容

#ASC#

J Vasc Surg ：无症状颈动脉狭窄与脑灌注不足有关

2021-03-19

quxin068 (审核中...)

前往app查看评论内容

#ASC#

2020 POST-ASCO：胶质母细胞瘤治疗的现状与未来

2020-11-06

quxin068 (审核中...)

前往app查看评论内容

#ASC#

FXR激动剂ASC42治疗NASH：美国FDA已批准IND

2020-10-31

quxin068 (审核中...)

前往app查看评论内容

#ASC#

ASCO前沿 | 阿帕替尼在肝癌等实体瘤治疗中获得突破性进展

2021-03-03

quxin068 (审核中...)

前往app查看评论内容

#ASC#

OCC 2020丨颠覆性试验结果！鱼油用于ASCVD防治是时候了吗？

2020-06-24

quxin068 (审核中...)

前往app查看评论内容

#ASC#

ASCO 2020：三阴性乳腺癌节拍化疗探索（SYSUCC-001研究）

2020-12-02

quxin068 (审核中...)

前往app查看评论内容

#ASC#

赵冬：ASCVD一级预防，LDL-C目标值和安全性再探讨

2021-07-23

科室
- - 订阅+
  - 更多科室
工具
服务